Antibody Drug Conjugates

Overview and Download

Published Date: 04/10/2013
Category: Therapies & Markets


Antibody Drug Conjugates or ADCs are a new class of therapeutic agents that combine the advantages of potent cytotoxic agents with selective targeting of a monoclonal antibody. Two ADCs have been approved Seattle Genomics/Takeda’s Adcetris (2011) and Roche’s Kadcyla (2013) - this has stimulated considerable investment in the field.

Further Details

Table of Contents


The trio of components

History of the ADC Market

1.       Case Study: The withdrawal of Pfizer’s Mylotarg, 2010

The ADC Market: Historic Challenges

Recent Developments in the ADC Market

2.       Recent FDA and EMA Approvals

Development of Stable Platforms for ADC

Collaborations Rife

Global ADC Market

Adcetris drives market growth, 2012

Rapid growth of Kadcyla in first-half 2013

Key Players

Future Outlook

3.       ADC Platform Technology

4.       Emerging Players

5.       Ambrx ADC Technology

6.       CytomX Probody Technology

The ADC Pipeline

7.       Key Pipeline Highlights:

Leading products of commercial interest include:

8.       Inotuzumab ozogamicin (Pfizer)

9.       SAR3419 (Sanofi)

10.   PSMA-ADC (Progenic)

SWOT Analysis


Companies mentioned

Useful websites